Improved macromolecules and methods for designing same
US-2025215407-A1 · Jul 3, 2025 · US
This page is not indexed by search engines while we improve data quality.
Offen Daniel patents
Offen Daniel is listed as an inventor on 42 patents in our database. Major assignees and classification codes are summarized below.
| Metric | Value |
|---|---|
| Inventor | Offen Daniel |
| Total patents | 42 |
| First publication | Mar 26, 2015 |
| Latest publication | Jul 3, 2025 |
Notable patents
Publications ranked by popularity score, then publication date.
Cannabinoid-lipid conjugates, methods for producing the same and uses thereof
US-2024398839-A1 · Dec 5, 2024 · US
Compositions comprising extracellular vesicles and an active agent and uses thereof
US-2024245720-A1 · Jul 25, 2024 · US
Vesicles comprising a pten inhibitor and uses of same
US-2023330130-A1 · Oct 19, 2023 · US
Vesicles comprising a PTEN inhibitor and uses of same
US-11648260-B2 · May 16, 2023 · US
Cannabidiol-containing compositions and uses thereof
US-2023115463-A1 · Apr 13, 2023 · US
Peptides for the treatment of renal disorders
US-2022251153-A1 · Aug 11, 2022 · US
Mesenchymal stem cells for the treatment of CNS diseases
US-11185572-B2 · Nov 30, 2021 · US
Mesenchymal cell-derived exosomes to treat neurological disorders
US-2021361717-A1 · Nov 25, 2021 · US
Mesenchymal cell-derived exosomes to treat neurological disorders
US-11129852-B2 · Sep 28, 2021 · US
Recent patents
Latest publications not already listed above.
PERK inhibitors and uses thereof in treating diseases associated with aggregation-prone proteins
US-11104651-B2 · Aug 31, 2021 · US
Methods and compositions for modulating myeloperoxidase (mpo) expression
US-2021214699-A1 · Jul 15, 2021 · US
Methods and compositions for modulating myeloperoxidase (mpo) expression
US-2021121539-A1 · Apr 29, 2021 · US
Vesicles comprising a pten inhibitor and uses of same
US-2021077520-A1 · Mar 18, 2021 · US
Isolated cells and populations comprising same for the treatment of CNS diseases
US-10869899-B2 · Dec 22, 2020 · US
Treatment for parkinsonian patients with mutations in the lrrk2 gene
US-2020370040-A1 · Nov 26, 2020 · US
Perk inhibitors and uses thereof in treating diseases associated with aggregation-prone proteins
US-2020331865-A1 · Oct 22, 2020 · US
Genetically modified muscle cells which express neurotrophic factors
US-10744162-B2 · Aug 18, 2020 · US
Perk inhibitors and uses thereof in treating diseases associated with aggregation-prone proteins
US-10723706-B2 · Jul 28, 2020 · US
Methods of treating alzheimer's disease
US-2020009180-A1 · Jan 9, 2020 · US
Mesenchymal cell-derived exosomes to treat neurological disorders
US-2019209621-A1 · Jul 11, 2019 · US
Genetically modified muscle cells which express neurotrophic factors
US-2019201452-A1 · Jul 4, 2019 · US
Combination treatment for amyotrophic lateral sclerosis (ALS)
US-10220077-B2 · Mar 5, 2019 · US
Perk inhibitors and uses thereof in treating diseases associated with aggregation-prone proteins
US-2019010130-A1 · Jan 10, 2019 · US
Mesenchymal stem cells for the treatment of cns diseases
US-2018333458-A1 · Nov 22, 2018 · US
Mesenchymal stem cells for the treatment of CNS diseases
US-10052363-B2 · Aug 21, 2018 · US
Peptides for the treatment of neurodegenerative diseases
US-10040836-B2 · Aug 7, 2018 · US
Isolated cells and populations comprising same for the treatment of cns diseases
US-2018112185-A1 · Apr 26, 2018 · US
Isolated cells and populations comprising same for the treatment of CNS diseases
US-9879225-B2 · Jan 30, 2018 · US
Scaffold-seeded oral mucosa stem cells
US-2018008648-A1 · Jan 11, 2018 · US
Major assignees
Companies most often associated with this inventor's publications.
| Assignee | Patents |
|---|---|
| Univ Ramot | 33 |
| Ramot At Tel-Aviv Univ Ltd | 9 |
| Brainstorm Cell Therapeutics Ltd | 6 |
| Yeda Res & Dev | 4 |
| Technion Res & Dev Foundation | 4 |
Top CPC classifications
Most common classification codes across this inventor's patents.
| CPC | Patents |
|---|---|
| A61P25/00 | 20 |
| A61P25/28 | 19 |
| A61K35/28 | 17 |
| A61K35/12 | 12 |
| C12N2501/11 | 10 |